Classifications

• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
  • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
  • G01N2333/76—Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2496/00—Reference solutions for assays of biological material
  • G01N2496/05—Reference solutions for assays of biological material containing blood cells or plasma
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
  • Y10T436/00—Chemistry: analytical and immunological testing
  • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
  • Y10T436/104998—Glucose, ketone, nitrate standard or control
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
  • Y10T436/00—Chemistry: analytical and immunological testing
  • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
  • Y10T436/105831—Protein or peptide standard or control [e.g., hemoglobin, etc.]

Definitions

• This invention relates to a synthetic control standard for use in the determination of cerebrospinal fluid proteins and other constituents.
• Cerebrospinal fluid is a clear, colorless fluid which is contained in the subarachnoid spaces of the brain and spinal cord and the ventricles of the brain. It contains a few lymphocytes and has a protein content of about 15 to 45 mg. per 100 ml. (mg. percent). Under certain patient conditions, for example, brain damage, brain or spinal tumors, it is desired to assay the cerebrospinal fluid for total protein content and other parameters.
• cerebrospinal fluids are precious specimens.
• cerebrospinal fluid protein As with other biological fluid materials, it is desirable to employ control standards of known composition for comparison with the patients sample.
• these control standards have comprised carefully collected and processed human cerebrospinal fluid.
• the product is costly.
• cerebrospinal (fluid is collected in such small quantities the material tends to deteriorate over the normal storage period required for collection of a suitable quantity for sale such as a liter or more. Enzymes in the fluid will tend to react with other constituents and product break-down products. Because of the numerous small samples which make up any collection of significant volume, the risk of bacterial contamination is greater than in ordinary blood serum collection.
• the human cerebrospinal fluid material is diflicult to handle in processing since it does not lyophilize readily. Because its mass is relatively small, it forms a fine powder which tends to collect on the upper walls and closure of the sample bottles with a consequent loss of material upon opening the closure and reconstitution with water prior to use.
• a synthetic control standard for the determination of cerebrospinal fluid is prepared from normal blood serum by dilution with a reagent comprising glucose and chloride ion in aqueous solution to a level whereby the total protein concentration ranges from about 30 to about 145 mg. percent. It is preferred that the diluted serum contains from about 40 to about 200 mg. percent glucose and from about to about 130 meq. per liter of chloride ion.
• the chloride ion can be provided by use of an aqueous solution of an alkali metal chloride, preferably sodium chloride.
• the chloride salt and the glucose preferably are analytical or reagent grade materials.
• pre-alburnin is a special fraction obtained from blood serum and is described, for example, by Got, et al., Isolement et caractrisation dune pralbumine du serum
• the aqueous solution is lyophilized to a dry material.
• the lyophilized material is improved by the addition of a small amount of gum acacia prior to lyophilization, for example, on the order of about 0.1%. This improved lyophilized, dry material can be readily reconstituted with water prior to use without product loss on the container closure.
• the synthetic cerebrospinal fluid control standard made as described herein has been found to produce much sharper bands in the electrophoretic pattern in actual use than obtained with the normal human cerebrospinal fluid. This is an added advantage of the invention in practice and enables the technician to improve the accuracy of the control procedures.
• EXAMPLE 1 A synthetic control standard for use in the determination of cerebrospinal fluid is prepared as follows:
• Human blood serum from which the clotting factors have been removed is diluted with an aqueous solution of glucose and sodium chloride containing 6.38 grams of NaCl and 600 mg. of glucose per liter.
• the serum is thereby diluted to a total protein concentration of 110 mg. per ml. by admixing 65 parts by volume of the diluent solution with one part by volume of the serum.
• To one liter of the diluted serum is then added 10 ml. of a 10% solution of gum acacia in water.
• the resulting solution is then filled in 3 ml. aliquots into 5 ml. bottles and lyophilized.
• the lyophilized, dry material is stored at 2 to 8 C. until required for use. In use, the dry material is reconstituted by dilution with 3 ml. of distilled water per bottle.
• control standards prepared in Examples 1 and 2, above are used in the same manner as an unknown cerebrospinal fluid for comparison with the patients sample to provide a check on the analytical determination.
• the method of making a synthetic control standard for use in the determination of cerebrospinal fluid constituents comprising diluting normal blood serum with an aqueous diluent containing from about to about 200 mg. per 100 ml. of glucose and from about to about 130 milliequivalents per liter of chloride ion to a level at which the total protein concentration ranges from about 30 to about 145 mg. per ml.
• the method of claim 1 including the additional steps of admixing the liquid control standard with about 0.1% gum acacia and lyophilizing to a dry, powdered material.
• a synthetic control standard for use in the determination of cerebrospinal fluid comprising normal blood serum diluted with an aqueous diluent containing from about 40 to about 200 mg. per 100 ml. of glucose and from about 80 to about milliequivalents per liter of chloride ion to a level at which the total protein concentration ranges from about 30 to about mg. per 100 ml.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Hematology (AREA)
• Engineering & Computer Science (AREA)
• Molecular Biology (AREA)
• Biomedical Technology (AREA)
• Chemical & Material Sciences (AREA)
• Immunology (AREA)
• Urology & Nephrology (AREA)
• Biotechnology (AREA)
• Microbiology (AREA)
• Cell Biology (AREA)
• Food Science & Technology (AREA)
• Medicinal Chemistry (AREA)
• Physics & Mathematics (AREA)
• Analytical Chemistry (AREA)
• Biochemistry (AREA)
• General Health & Medical Sciences (AREA)
• General Physics & Mathematics (AREA)
• Pathology (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Applications Claiming Priority (1)

Publications (1)

Family

ID=22895733

Family Applications (1)

Country Status (8)

Cited By (6)

Families Citing this family (2)

• 1972
  • 1972-03-24 US US00237905A patent/US3753925A/en not_active Expired - Lifetime
• 1973
  • 1973-03-19 ZA ZA731898A patent/ZA731898B/xx unknown
  • 1973-03-20 JP JP48032518A patent/JPS4931390A/ja active Pending
  • 1973-03-21 BE BE129041A patent/BE797081A/xx unknown
  • 1973-03-22 DE DE2314263A patent/DE2314263C2/de not_active Expired
  • 1973-03-23 CA CA166,819A patent/CA985996A/en not_active Expired
  • 1973-03-23 FR FR7310485A patent/FR2185248A5/fr not_active Expired
  • 1973-03-26 GB GB1444873A patent/GB1372812A/en not_active Expired

Also Published As

Similar Documents

Legal Events